For our analysis, we assigned each fish taxon to one of 4 trophic groups using the information about diet in the literature [23], and in previous Mediterranean studies [24]: apex predators, carnivores, herbivores, and (zoo planktivores.
In this study, the apex of Si nanowires covered with a considerable number of Ni atoms, which can be regarded as a system with a high Ni/Si atomic ratio, causing the formation of a metal-rich phase (Ni3Si2) at the Ni-coated part of Ni-silicide.
The largest study conducted so far with bortezomib was the APEX study, a 669 patient phase 3 study, comparing bortezomib with high-dose dexamethasone in heavily pretreated patients with relapsed multiple myeloma.
Several studies after the APEX trial analysis confirmed the positive effects of PIs on bone formation and resorption markers [ 114– 114].
Studies on these apex predator groups have been conducted in the north temperate Atlantic Ocean (Spalding et al. 2007), suggesting that monitoring these taxa is feasible.
Our study demonstrates that APEX is a powerful tool for mapping macromolecular complexes in living cells, and can identify proteins and pathways that have been missed by traditional approaches.
We first utilized mitochondrial calcium uniporter (MCU) as a positive control that was used in the previous APEX study (Martell et al. 2012) to validate the performance of APEX/APEX2 staining in our system.
Birnbaum et al. [ 15] reported that the tentative Arabidopsis ortholog is most expressed in all tissues studied nearest the apex of the root (Additional file 3).
The approval of febuxostat was based on the data from three phase 3 clinical trials, Allopurinol- and Placebo-controlled Efficacy study of febuxostat (APEX) [ 28], Febuxostat versus Allopurinol Controlled Trial (FACT) [ 29], and CONFIRMS [ 30].
The Arthroplasty Pain Experience (APEX) study is a single-centre double-blind RCT that is currently being conducted at the Avon Orthopaedic Centre, one of the largest orthopaedic centres in the UK.
A prospective algorithm for bortezomib dose reductions as was derived from the SUMMIT and CREST trials and applied in the APEX study is recommended for individuals who receive the agent (Table 1).
